Dr. Elihu Estey
Add to your Care-Team
Dr. Elihu Estey
Dr. Elihu Estey
Internal Medicine - Oncology
New York, NY
I specialize in
Internal Medicine - Oncology
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
Johns Hopkins University School of Medicine
Yale University School of Medicine
Gemtuzumab ozogamicin: time to resurrect?
J. Clin. Oncol., Nov;30(32):3921-3 (2012)
Intensity of conditioning for allogeneic haemopoetic cell transplantation.
Lancet Oncol., Oct;13(10):966-8 (2012)
Management of acute promyelocytic leukemia: implications for treatment of other cancers.
Oncology (Williston Park, N.Y.)., Jul;26(7):641, 646-7 (2012)
Acute myeloid leukemia with normal cytogenetics.
Curr Oncol Rep., Oct;14(5):359-68 (2012)
Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Haematologica., Jul (2012)
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica., Nov;97(11):1736-42 (2012)
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia.
Haematologica., Sep;97(9):1401-4 (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.
Blood., Jun;119(26):6198-208 (2012)
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Biol. Blood Marrow Transplant., Aug;18(8):1211-8 (2012)
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.
Am. J. Hematol., Jan;87(1):89-99 (2012)
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
Haematologica., May;97(5):739-42 (2012)
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
J. Clin. Oncol., Nov;29(33):4417-23 (2011)
Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
Cancer., May;118(9):2420-3 (2012)
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Br. J. Haematol., Oct;155(2):182-9 (2011)
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
J. Clin. Oncol., Jul;29(20):2743-6 (2011)
Treatment of acute myeloid leukemia in the elderly.
Haematologica., Jun;96(6):795-8 (2011)
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
Haematologica., Jun;96(6):914-7 (2011)
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype.
Haematologica., Apr;96(4):631-2 (2011)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
J. Clin. Oncol., Mar;29(9):1190-7 (2011)
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Blood., Oct;116(14):2420-8 (2010)
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
J. Clin. Oncol., Apr;28(10):1766-71 (2010)
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Br. J. Haematol., Mar;148(6):944-7 (2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood., Jan;115(3):453-74 (2010)
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.
Immunity., Nov;31(5):834-44 (2009)
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
J. Clin. Oncol., Oct;27(28):4741-6 (2009)
Incorporating novel treatment strategies into conventional therapy.
Clin Adv Hematol Oncol., Jun;7(6):4-7 (2009)
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Exp. Hematol., Jul;37(7):784-90 (2009)
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Leukemia., Sep;23(9):1605-13 (2009)
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.
Proc. Natl. Acad. Sci. U.S.A., Jan;106(4):1187-92 (2009)
Treatment of acute myeloid leukemia.
Haematologica., Jan;94(1):10-6 (2009)
The power of comparative studies.
Leuk. Res., May;33(5):610-2 (2009)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood., Jun;113(24):6215-24 (2009)
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer., Dec;113(11):3181-5 (2008)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood., Feb;113(9):1875-91 (2009)
Patient-specific dose finding based on bivariate outcomes and covariates.
Biometrics., Dec;64(4):1126-36 (2008)
Older adults: should the paradigm shift from standard therapy?
Best Pract Res Clin Haematol., Mar;21(1):61-6 (2008)
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clin. Cancer Res., Feb;14(3):721-30 (2008)
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clin. Cancer Res., Jan;14(2):509-14 (2008)
Epidemiology of myelodysplastic syndromes.
Semin. Hematol., Jan;45(1):8-13 (2008)
Accounting for patient heterogeneity in phase II clinical trials.
Stat Med., Jul;27(15):2802-15 (2008)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood., Oct;110(7):2302-8 (2007)
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
Mod. Pathol., Aug;20(8):811-20 (2007)
Advances in the management of AML in the elderly.
Clin Adv Hematol Oncol., Mar;5(3):185-7 (2007)
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer., Apr;109(7):1355-9 (2007)
Building and validating a prognostic index for biomarker studies.
Cancer Biomark., 2(3-4):97-101 (2006)
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
J Biopharm Stat., 16(5):623-38 (2006)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Br. J. Haematol., Oct;135(2):165-73 (2006)
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
Blood., Oct;108(7):2358-65 (2006)
Some ethical issues in phase II trials in acute leukemia.
Clin Adv Hematol Oncol., Feb;4(2):95 (2006)
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
Cancer., Jul;107(1):116-24 (2006)
General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia.
Semin. Hematol., Apr;43(2):89-95 (2006)
Some ethical issues in phase II trials in acute leukemia.
Clin Adv Hematol Oncol., Dec;3(12):943-8 (2005)
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrob. Agents Chemother., Jan;50(1):143-7 (2006)
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Clin Adv Hematol Oncol., Apr;1(4):220-5 (2003)
"3+7" therapy for the treatment of acute myeloid leukemia. CON.
Clin Adv Hematol Oncol., Feb;3(2):129-132, 141 (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer., Oct;104(7):1442-52 (2005)
CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
Br. J. Haematol., Jul;130(1):83-6 (2005)
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leuk. Res., Apr;29(4):459-62 (2005)
Modulation of angiogenesis in patients with myelodysplastic syndrome.
Best Pract Res Clin Haematol., Dec;17(4):623-39 (2004)
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer., May;100(9):1884-91 (2004)
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
J. Clin. Oncol., Apr;22(7):1287-92 (2004)
Treatment of acute myelogenous leukemia.
Oncology (Williston Park, N.Y.)., Mar;16(3):343-52, 355-6; discussion 357, 362, 365-6 (2002)
Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
Am. J. Clin. Pathol., Mar;121(3):402-7 (2004)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
J. Clin. Oncol., Dec;21(24):4642-9 (2003)
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
Blood., Mar;103(5):1815-22 (2004)
The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer., Oct;98(8):1681-8 (2003)
Treatment options for relapsed acute promyelocytic leukaemia.
Best Pract Res Clin Haematol., Sep;16(3):521-34 (2003)
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
Ann Pharmacother., Sep;37(9):1182-5 (2003)
Adaptive randomization in a treatment study of patients with adverse karyotype acute myeloid leukemia.
Curr Oncol Rep., Sep;5(5):390 (2003)
Early blast clearance by remission induction as a prognostic factor in acute myeloid leukemia.
Curr Oncol Rep., Sep;5(5):389 (2003)
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica., Jul;88(7):733-6 (2003)
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood., Nov;102(9):3097-9 (2003)
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Blood., Sep;102(5):1622-5 (2003)
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
J. Clin. Oncol., May;21(9):1722-7 (2003)
New designs for phase 2 clinical trials.
Blood., Jul;102(2):442-8 (2003)
Current challenges in therapy of myelodysplastic syndromes.
Curr. Opin. Hematol., Jan;10(1):60-7 (2003)
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer., Nov;95(9):1923-30 (2002)
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood., Jun;99(12):4343-9 (2002)
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
J. Clin. Oncol., Feb;20(3):665-73 (2002)
Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
Leukemia., Nov;13(11):1735-40 (1999)
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Oncology (Williston Park, N.Y.)., Nov;12(11A):81-6 (1998)
NCCN Acute Leukemia Practice Guidelines. The National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.)., Nov;10(11 Suppl):205-21 (1996)
Chemotherapy versus transplants for acute myelogenous leukemia in second remission.
Leukemia., Jan;10(1):13-9 (1996)
Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
Leukemia., May;9(5):929-32 (1995)
The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.
Leuk. Lymphoma., Mar;17(1-2):79-85 (1995)
The prognostic significance of auer rods in myelodysplasia.
Br. J. Haematol., Sep;85(1):67-76 (1993)
Granulocytic sarcoma of the colon.
Gastroenterology., Feb;100(2):555-9 (1991)
Dr. Elihu Estey M